ANCA associated glomerulonephritis
Conditions
Interventions
Low risk group:Induction remission stage: Glucocorticoid + cyclophosphamide
Maintain remission stage: Hormone + azathioprine / methotrexate / mycophenolate mofetil
Medium risk group:Induction remission stage: Methylprednisolone + intravenous cyclophosphamide or rituximab
Maintain remission stage: Hormone + azathioprine / mycophenolate mofetil / rituximab
High risk group:Induction: Methylprednisolone + cyclophosphamide + rituximab + plasma exchange
Maintain: Hormone + azathioprine / mycophenolate mofetil / rituximab
control group:Induction: Methylprednisolone + intravenous cyclophosphamide
Maintain: Hormone + azathioprine / methotrexate / mycophenolate mofetil
Sponsors
Children's Hospital Affiliated to Chongqing Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients under the age of 18 years old with regular follow-up in the hospital; 2. All the children in the group met the following inclusion and exclusion criteria: (1) In line with the definition of ANCA related vasculitis in the 2012 U.S. chapel hill conference; (2) Renal damage was identified.
Exclusion criteria
Exclusion criteria: 1. Patients with secondary vasculitis (such as systemic lupus erythematosus, Henoch Schonlein purpura, drugs, tumors, infections, etc.); 2. Patients with primary renal diseases (such as IgA nephropathy, membranous nephropathy and anti glomerular basement membrane nephritis).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ARRS score;Effectiveness;adverse event; | — |
Countries
China
Contacts
Public ContactMo Wang
Children's Hospital Affiliated to Chongqing Medical University
Outcome results
None listed